Capricor Therapeutics Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CAPR Nasdaq 2836 http://capricor.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Capricor Therapeutics Inc

Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates - May 13th, 2019 3:15 pm
Capricor: 1Q Earnings Snapshot - May 13th, 2019 2:06 pm
Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update - May 13th, 2019 2:00 pm
Capricor Therapeutics, Inc. to Host Earnings Call - May 13th, 2019 12:30 pm
Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13 - May 6th, 2019 2:00 pm
Will Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Earnings Grow In The Years Ahead? - Apr 5th, 2019 8:52 am
Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update - Mar 28th, 2019 2:00 pm
Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28 - Mar 21st, 2019 6:00 am
Capricor Therapeutics, Inc. (NASDAQ:CAPR): Commentary On Fundamentals - Feb 21st, 2019 5:40 am
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy - Feb 6th, 2019 5:00 am
4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19) - Jan 24th, 2019 7:30 am
Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy - Jan 24th, 2019 5:00 am
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA - Jan 22nd, 2019 5:00 am
Does Capricor Therapeutics, Inc.’s (NASDAQ:CAPR) CEO Pay Reflect Performance? - Jan 18th, 2019 12:56 pm
Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth - Dec 27th, 2018 5:25 am
U.S. drug developer Capricor places Duchenne drug trial on hold - Dec 26th, 2018 4:58 am
Could The Capricor Therapeutics Inc (NASDAQ:CAPR) Ownership Structure Tell Us Something Useful? - Dec 4th, 2018 7:53 am
Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement - Nov 28th, 2018 6:35 am